Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.29) per share. This is a 30.95 percent increase over losses of $(0.42) per share from the same period last year.
Read original at benzingaStocks · News reference
8-K filing — Pulmatrix, Inc. (PULM)
Filed: 2026-08-13 AccNo: 0001493152-26-037592 Size: 294 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 13, 2026, 12:15 PM
- Checked
- Aug 13, 2026, 12:15 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Halper Sadeh LLC is Investigating Whether SLP, HUN, OLN, PULM are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The investigations concern whether shareholders are receiving fair consideration in these transactions, with concerns that insiders may benefit disproportionately and deal terms may prevent superior competing offers.
Read original at globenewswire-incEos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum
Eos SENOLYTIX presented preclinical data for its lead candidate PTC-2105, a mitochondrial-targeted geropeptide showing improvements in body composition with lean mass gains and fat reduction without the muscle loss associated with GLP-1 therapies. The company also announced a merger agreement with Pulmatrix, Inc., expected to close in Q3 2026 under the new ticker symbol MTXL. Preclinical studies demonstrated extended survival in aged mice and prevention of age-related decline.
Read original at globenewswire-inc